Hanan Eissa

Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis

Mahmoud E. Youssef, Eslam E. Abd El-Fattah, Hanan Eissa et al. · Frontiers in Pharmacology · 2021 · 60 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application

Sameh Saber, Mahmoud E. Youssef, Ahmed Gaafar Ahmed Gaafar et al. · Biomedicine & Pharmacotherapy · 2021 · 60 citations · Full text

Medicine, Oncology, Pharmacology +12

A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: Role of oxidative stress, gut microbiota, and PPARγ activation

Eman M. Khalaf, Hanan M. Hassan, Ahmed M. El-Baz et al. · European Journal of Pharmacology · 2022 · 28 citations

Medicine, Cardiology, Pharmacology +17

AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma

Eslam E. Abd El-Fattah, Sameh Saber, Mahmoud E. Youssef et al. · Frontiers in Pharmacology · 2022 · 27 citations · Full text

Medicine, Oncology, Pharmacology +14

Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis

Ahmed A. Shaaban, Simona Cavalu, Adrian Marius Maghiar et al. · Biomedicine & Pharmacotherapy · 2022 · 25 citations · Full text

Life Sciences, Immunology, Pharmacology +17